Involvement of DPP‐IV catalytic residues in enzyme–saxagliptin complex formation
暂无分享,去创建一个
W. Metzler | J. Yanchunas | C. Weigelt | K. Kish | H. Klei | D. Xie | Yaqun Zhang | M. Corbett | James K. Tamura | B. He | L. Hamann | M. Kirby | J. Marcinkeviciene
[1] A. Berger,et al. On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.
[2] R. Shulman,et al. High resolution nuclear magnetic resonance study of the histidine--aspartate hydrogen bond in chymotrypsin and chymotrypsinogen. , 1972, Journal of molecular biology.
[3] S. French,et al. On the treatment of negative intensity observations , 1978 .
[4] P. J. Hore,et al. Solvent suppression in Fourier transform nuclear magnetic resonance , 1983 .
[5] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.
[6] J. Navaza,et al. AMoRe: an automated package for molecular replacement , 1994 .
[7] P. Frey,et al. A new concept for the mechanism of action of chymotrypsin: the role of the low-barrier hydrogen bond. , 1997, Biochemistry.
[8] Z. Otwinowski,et al. Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[9] L. Polgár,et al. Low Barrier Hydrogen Bond Is Absent in the Catalytic Triads in the Ground State but Is Present in a Transition-state Complex in the Prolyl Oligopeptidase Family of Serine Proteases* , 1997, The Journal of Biological Chemistry.
[10] R J Read,et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.
[11] P. Frey,et al. Fractionation factors and activation energies for exchange of the low barrier hydrogen bonding proton in peptidyl trifluoromethyl ketone complexes of chymotrypsin. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[12] T. Hughes,et al. NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. , 1999, Biochemistry.
[13] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[14] Victor S. Lobanov,et al. High-Density Miniaturized Thermal Shift Assays as a General Strategy for Drug Discovery , 2001 .
[15] C. Durinx,et al. Kinetic Investigation of Chemokine Truncation by CD26/Dipeptidyl Peptidase IV Reveals a Striking Selectivity within the Chemokine Family* , 2001, The Journal of Biological Chemistry.
[16] Bo Ahrén,et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. , 2002, Diabetes care.
[17] Robert N. Goldberg,et al. Thermodynamic Quantities for the Ionization Reactions of Buffers , 2002 .
[18] T. Hughes,et al. 1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. , 2002, Journal of medicinal chemistry.
[19] A. D'arcy,et al. High-resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-[([2-[(5-iodopyridin-2-yl)amino]-ethyl]amino)-acetyl]-2-cyano-(S)-pyrrolidine. , 2003, Acta crystallographica. Section D, Biological crystallography.
[20] Sven Branner,et al. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog , 2003, Nature Structural Biology.
[21] Eberhard Standl,et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. , 2004, Diabetes care.
[22] Biching Sang,et al. Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation , 2004, Protein science : a publication of the Protein Society.
[23] Xin Chen,et al. One Site Mutation Disrupts Dimer Formation in Human DPP-IV Proteins* , 2004, Journal of Biological Chemistry.
[24] Sven Branner,et al. Tyrosine 547 Constitutes an Essential Part of the Catalytic Mechanism of Dipeptidyl Peptidase IV* , 2004, Journal of Biological Chemistry.
[25] G. Scapin,et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.
[26] R. Parker,et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.
[27] Giovanni Pacini,et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. , 2005, Diabetes care.
[28] Michael L Doyle,et al. Decrypting the Biochemical Function of an Essential Gene from Streptococcus pneumoniae Using ThermoFluor® Technology* , 2005, Journal of Biological Chemistry.
[29] W. Metzler,et al. Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118). , 2006, Archives of biochemistry and biophysics.